Shahzad Malik is a General Partner at Advent Life Sciences, a London-based venture capital firm he co-founded in 2010 as. See sector focus and contact routes.
Shahzad Malik is a General Partner at Advent Life Sciences, a London-based venture capital firm he co-founded in 2010 as a spin-out from Advent Venture Partners, bringing over two decades of experience since joining the original firm in 1999 with backgrounds in science, clinical medicine, and international finance. His investment thesis targets early- to mid-stage biotechnology, pharmaceuticals, medical devices, and diagnostics companies across Europe and the United States, focusing on Series A and B rounds. Malik typically deploys checks ranging from $25,000 to $5 million and has served as the lead partner on 26 deals, including his latest investment in Relief Cardiovascular. Notable portfolio companies where he serves on the board include Orphalan, Moximed, Curve Therapeutics, and Proximie, alongside Highlight Therapeutics and Axonics Modulation Technologies. While specific public writing is not detailed in available sources, his distinctive point of view emphasizes backing first-in-class or best-in-class solutions in drug discovery, medical technology, and vaccines. Malik also holds an MD from Cambridge University and an MA in Physiological Sciences
StartupFundraising tracks this investor record from SEC filings and announced rounds, updating focus, location and portfolio history as new data lands. Use it to gauge fit before an outreach, then widen the search to investors in London.
Investors like Shahzad Malik · Full investor directory · Investor access · Company funding database